Unknown

Dataset Information

0

Eculizumab in paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome: 10-year pharmacovigilance analysis.


ABSTRACT: Eculizumab is the first and only medication approved for paroxysmal nocturnal haemoglobinuria (PNH) and atypical haemolytic uraemic syndrome (aHUS) treatment. However, eculizumab safety based on long-term pharmacovigilance is unknown. This analysis summarises safety data collected from spontaneous and solicited sources from 16 March 2007 through 1 October 2016. Cumulative exposure to eculizumab was 28 518 patient-years (PY) (PNH, 21 016 PY; aHUS, 7502 PY). Seventy-six cases of meningococcal infection were reported (0·25/100 PY), including eight fatal PNH cases (0·03/100 PY). Susceptibility to meningococcal infections remained the key risk in patients receiving eculizumab. The meningococcal infection rate decreased over time; related mortality remained steady. The most commonly reported serious nonmeningococcal infections were pneumonia (11·8%); bacteraemia, sepsis and septic shock (11·1%); urinary tract infection (4·1%); staphylococcal infection (2·6%); and viral infection (2·5%). There were 434 reported cases of eculizumab exposure in pregnant women; of 260 cases with known outcomes, 70% resulted in live births. Reporting rates for solid tumours (?0·6/100 PY) and haematological malignancies (?0·74/100 PY) remained stable over time. No new safety signals affecting the eculizumab benefit-risk profile were identified. Continued awareness and implementation of risk mitigation protocols are essential to minimise risk of meningococcal and other Neisseria infections in patients receiving eculizumab.

SUBMITTER: Socie G 

PROVIDER: S-EPMC6594003 | biostudies-literature | 2019 Apr

REPOSITORIES: biostudies-literature

altmetric image

Publications

Eculizumab in paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome: 10-year pharmacovigilance analysis.

Socié Gérard G   Caby-Tosi Marie-Pierre MP   Marantz Jing L JL   Cole Alexander A   Bedrosian Camille L CL   Gasteyger Christoph C   Mujeebuddin Arshad A   Hillmen Peter P   Vande Walle Johan J   Haller Hermann H  

British journal of haematology 20190215 2


Eculizumab is the first and only medication approved for paroxysmal nocturnal haemoglobinuria (PNH) and atypical haemolytic uraemic syndrome (aHUS) treatment. However, eculizumab safety based on long-term pharmacovigilance is unknown. This analysis summarises safety data collected from spontaneous and solicited sources from 16 March 2007 through 1 October 2016. Cumulative exposure to eculizumab was 28 518 patient-years (PY) (PNH, 21 016 PY; aHUS, 7502 PY). Seventy-six cases of meningococcal infe  ...[more]

Similar Datasets

| S-EPMC5410989 | biostudies-literature
| S-EPMC8496203 | biostudies-literature
| S-EPMC3822313 | biostudies-other
| S-EPMC4400463 | biostudies-literature
| S-EPMC3744747 | biostudies-literature
| S-EPMC7045788 | biostudies-literature
| S-EPMC6452204 | biostudies-literature
| S-EPMC6660499 | biostudies-literature
| S-EPMC5534672 | biostudies-other
| S-EPMC8052220 | biostudies-literature